ES2180575T3 - Pirido(2,3-b)(1,4)benzodiazepinonas como ligando de receptor m2 para el tratamiento de trastornos neurologicos. - Google Patents

Pirido(2,3-b)(1,4)benzodiazepinonas como ligando de receptor m2 para el tratamiento de trastornos neurologicos.

Info

Publication number
ES2180575T3
ES2180575T3 ES94914039T ES94914039T ES2180575T3 ES 2180575 T3 ES2180575 T3 ES 2180575T3 ES 94914039 T ES94914039 T ES 94914039T ES 94914039 T ES94914039 T ES 94914039T ES 2180575 T3 ES2180575 T3 ES 2180575T3
Authority
ES
Spain
Prior art keywords
treatment
neurological disorders
receptor
benzodiazepinones
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94914039T
Other languages
English (en)
Inventor
R Tyler Mccabe
Bryan R Wilson
Christopher A Rhodes
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mannkind Corp
Original Assignee
Pharmaceutical Discovery Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmaceutical Discovery Corp filed Critical Pharmaceutical Discovery Corp
Application granted granted Critical
Publication of ES2180575T3 publication Critical patent/ES2180575T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)

Abstract

SE DESCRIBEN LIGANTES DEL RECEPTOR M2 MUSCARINICO QUE SON ADECUADOS PARA EL TRATAMIENTO DE ENFERMEDADES NEUROLOGICAS, QUE PUEDEN ADMINISTRARSE CON EFECTOS COLATERALES MINIMOS. TAMBIEN SE DESCRIBE UN METODO DE SINTESIS DE LOS COMPUESTOS.
ES94914039T 1993-04-05 1994-04-05 Pirido(2,3-b)(1,4)benzodiazepinonas como ligando de receptor m2 para el tratamiento de trastornos neurologicos. Expired - Lifetime ES2180575T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US4287293A 1993-04-05 1993-04-05

Publications (1)

Publication Number Publication Date
ES2180575T3 true ES2180575T3 (es) 2003-02-16

Family

ID=21924192

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94914039T Expired - Lifetime ES2180575T3 (es) 1993-04-05 1994-04-05 Pirido(2,3-b)(1,4)benzodiazepinonas como ligando de receptor m2 para el tratamiento de trastornos neurologicos.

Country Status (11)

Country Link
US (1) US5712269A (es)
EP (2) EP0693070B1 (es)
JP (1) JP3638950B2 (es)
AT (1) ATE221067T1 (es)
AU (1) AU688318B2 (es)
CA (1) CA2159815A1 (es)
DE (1) DE69431050T2 (es)
DK (1) DK0693070T3 (es)
ES (1) ES2180575T3 (es)
PT (1) PT693070E (es)
WO (1) WO1994022861A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6528529B1 (en) 1998-03-31 2003-03-04 Acadia Pharmaceuticals Inc. Compounds with activity on muscarinic receptors
ITMI991452A1 (it) * 1999-07-01 2001-01-01 Mediolanum Farmaceutici Srl Antagonisti selettivi per i recettori m2 con struttura 5h-dibenzo b,fazepinica
AR025884A1 (es) * 1999-10-01 2002-12-18 Takeda Pharmaceutical Compuestos de amina ciclica, su produccion y su uso
WO2003089004A1 (fr) * 2002-04-19 2003-10-30 Takeda Pharmaceutical Company Limited Agents prophylactiques utilises pour prevenir l'infection par vih
AU2005263577C1 (en) 2004-07-16 2010-08-26 Proteosys Ag Muscarinic antagonists with PARP and SiR modulating activity as cytoprotective agents
EP2258358A3 (en) 2005-08-26 2011-09-07 Braincells, Inc. Neurogenesis with acetylcholinesterase inhibitor
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
KR20230085223A (ko) * 2008-12-04 2023-06-13 충시 위 고투과력을 가진 조성물 및 이의 적용
EP2379080A1 (en) 2009-01-13 2011-10-26 ProteoSys AG Pirenzepine as otoprotective agent
GB201510010D0 (en) 2015-06-09 2015-07-22 King S College London PDD and BPD compounds
GB201514928D0 (en) 2015-08-21 2015-10-07 King S College London PDD compounds
US20180339985A1 (en) 2015-08-21 2018-11-29 Femtogenix Limited Pdd compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH438343A (de) * 1962-11-08 1967-06-30 Thomae Gmbh Dr K Verfahren zur Herstellung von 5,6-Dihydro-6-oxo-11H-pyrido (2,3-b) (1,4)-benzodiazepinen
DE3735895A1 (de) * 1987-10-23 1989-05-03 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
DE3818299A1 (de) * 1988-05-30 1989-12-07 Thomae Gmbh Dr K Neue kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
GB9000302D0 (en) * 1990-01-06 1990-03-07 Pfizer Ltd Muscarinic receptor antagonists
DE4112014A1 (de) * 1991-04-12 1992-10-15 Thomae Gmbh Dr K Kondensierte diazepinone, verfahren zu ihrer herstellung und diese verbindungen enthaltende mittel zur behandlung von erkrankungen des zentralnervensystems und zur foerderung der cerebralen durchblutung

Also Published As

Publication number Publication date
EP0693070A1 (en) 1996-01-24
EP1120416A1 (en) 2001-08-01
EP0693070B1 (en) 2002-07-24
JPH08510999A (ja) 1996-11-19
CA2159815A1 (en) 1994-10-13
ATE221067T1 (de) 2002-08-15
DE69431050T2 (de) 2003-03-13
DK0693070T3 (da) 2002-11-11
US5712269A (en) 1998-01-27
AU688318B2 (en) 1998-03-12
PT693070E (pt) 2002-12-31
AU6626194A (en) 1994-10-24
DE69431050D1 (de) 2002-08-29
WO1994022861A1 (en) 1994-10-13
JP3638950B2 (ja) 2005-04-13

Similar Documents

Publication Publication Date Title
EG20218A (en) Process for preparing of substituted 3 aminoquinuclidines
HK1011933A1 (en) Indolinone compounds for the treatment of disease
ATE152111T1 (de) K-252a derivate
EP0876818A4 (en) THERAPEUTIC AGENT AGAINST NEURODEGENERATIVE DISORDERS
ES2180575T3 (es) Pirido(2,3-b)(1,4)benzodiazepinonas como ligando de receptor m2 para el tratamiento de trastornos neurologicos.
CA2149242A1 (en) Quinuclidine Derivative for Treatment of Inflammatory and Gastrointestinal Disorders
CA2167004A1 (en) Agent for treating mental disorders associated with cerebrovascular disorders
GB9212308D0 (en) Therapeutic compositions
ES2080736T3 (es) Uso de 2,3,4,5-tetrahidro-1h-3-benzazepinas en el tratamiento de trastornos neurologicos.
FI942400A (fi) Lääkeaine hermosairauksia vastaan
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen
IT1296613B1 (it) Farmaco per la cura dell'ircismo contenente un adrenocorticosteroide.
PH24501A (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones
PT889044E (pt) Derivados do 5-(heteroaril)alquil-3-oxo-pirido-(1,2-a)benzimidazole-4-carboxamida (pbi) uteis no tratamento de perturbacoes do sistema nervoso central
AU6896198A (en) Method for treating cerebral focal stroke
EP0462468A3 (en) 9-amino-2-phenylbicyclo(3.3.1)nonane and 9-amino-2-phenylbicyclo(3.3.1)-non-2-ene and therapeutic agents containing them
LV5780B4 (lv) Pretkonvulsiji triazolÚ4,5-c¾piridina atvasinajumi
SI0746556T1 (en) Tricyclic compounds having affinity for the 5-ht1a receptor
ZA974928B (en) Process for the preparation of organic salts of N'N-Diacetylcystine.
IL121597A0 (en) Novel optically pure amines for the treatment of central nervous system disorders